ChuiJ, Di GirolamoN, WakefieldD, CoroneoMT. The pathogenesis of pterygium: Current concepts and their therapeutic implications. Ocul Surf, 2008; 6:24–43.
2.
Di GirolamoN, ChuiJ, CoroneoMT, WakefieldD. Pathogenesis of pterygia: Role of cytokines, growth factors, and matrix metalloproteinases. Prog Retin Eye Res, 2004; 23:195–228.
3.
DetorakisET, SpandidosDA. Pathogenetic mechanisms and treatment options for ophthalmic pterygium: Trends and perspectives [Review]Int J Mol Med, 2009; 23:439–447.
4.
AngLP, ChuaJL, TanDT. Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol, 2007; 18:308–313.
5.
GovindenR, BhoolaKD. Genealogy, expression, and cellular function of transforming growth factor-beta. Pharmacol Ther, 2003; 98:257–265.
6.
KriaL, OhiraA, AmemiyaT. Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium. Acta Histochem, 1996; 98:195–201.
7.
Schuller-LevisGB, ParkE. Taurine and its chloramine: Modulators of immunity. Neurochem Res, 2004; 29:117–126.
8.
Schuller-LevisGB, MehtaPD, RudelliR, SturmanJA. Immunologic consequence of taurine deficiency in cats. J Leukoc Biol, 1990; 47:321–333.
9.
CondronCM, ToomeyDM, CaseyRGet al.Taurine protects against PMN dysfunction and death in urine. Urol Res, 2004; 32:338–345.
10.
GordonRE, ShakedAA, SolanoDF. Taurine protects hamster bronchioles from acute NO2-induced alterations: A histologic, ultrastructural, and freeze-fracture study. Am J Pathol, 1986; 125:585–600.
11.
KendelerBS. Taurine: An overview of its role in preventive medicine. Preventive Med, 1989; 18:79–100.
